海外の治験の状況「1」での検索結果
2657件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- Calcium supplementation during pregnancy in low-intake populations
- Pre-eclampsia Pregnancy and Childbirth Pre-eclampsia
- Argentina, Egypt, India, Peru, South Africa, Viet Nam
- 2004-04-01
Recruiting
- Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency;Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- Australia, Canada, Denmark, Estonia, New Zealand, Sweden, United States
- 2016-06-03
Not Recruiting
- Springfusor versus standard of care in administration of magnesium sulphate
- Pregnancy and Childbirth Preeclampsia, eclampsia;Pregnancy and Childbirth;Preeclampsia, eclampsia
- Uganda
- 2017-12-18
Not Recruiting
- Glucose Responses to Normal Meals In Non-diabetic Individuals
- Type 1 Diabetes; Type 1 Diabetes;Metabolic and Endocrine - Diabetes;Diet and Nutrition - Other diet and nutrition disorders
- Australia
- 2019-01-21
Not Recruiting
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY
- Arabia Saudi, Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czech Republic, Egypt, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea North, Lebano, Mexico, New Zealand, Norway, Poland, Russian Federation, Singapore, Slovakia, South Africa, Spain, Switzerland, Thailand, Turkey, United Arab Emirates, United States, Venezuela
- 2012-05-04
Not Recruiting
- A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Austria, Belgium, Germany, India, Netherlands, Poland, Russian Federation, South Africa, United Kingdom, United States
- 2012-04-30
Not Recruiting
- A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
- Diffuse Large B-cell Lymphoma;C83.3 - Diffuse large B-cell lymphoma
- Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czech Republic, Egypt, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Lebanon, Mexico, New Zealand, Norway, Peru, Poland, Russian Federation, Saudi Arabia, Singapore, Slovakia, Spain, Switzerland, Thailand, Turkey, United States, Venezuela, Bolivarian Republic of
- 2012-04-30
Not recruiting
- A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With Human Epidermal Growth Factor Receptor 2 (HER2)/Neu Positive Metastatic Breast Cancer
- Human Epidermal Growth Factor Receptor 2 (HER2)/Neu positive metastatic breast cancer
- Australia, Canada, France, Germany, Israel, United Kingdom, United States of America
- 2009-03-06
Not Recruiting
- Research Trial to Study inhibitor development in previously untreated or minimally exposed Children to two different commercially available types of Factor VIII. This is Phase IV open lable , randomized,Study comparing Plasma derived Factor VIII with Recombinant Factor VIII.
- Severe Hemophilia A
- Argentina, Austria, Belgium, Brazil, Chile, Czech Republic, Denmark, Egypt, Fiji, France, Germany, India, Iran (Islamic Republic of), Italy, Mexico, Poland, Portugal, Romania, Saudi Arabia, Slovakia, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States of America, Uruguay
- 2010-01-08
Not recruiting
- Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
- Non-Hodgkin's Lymphoma;Mantle Cell Lymphoma;Non-Hodgkin's Lymphoma;Mantle Cell Lymphoma;Non-Hodgkin's Lymphoma;Mantle Cell Lymphoma;Non-Hodgkin's Lymphoma;Mantle Cell Lymphoma
- Australia, Brazil, Canada, Mexico, New Zealand, Peru, United States
- 2009-04-03
Not recruiting
- Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
- Diffuse Large B-cell Lymphoma;Diffuse Large B-cell Lymphoma;Diffuse Large B-cell Lymphoma;Diffuse Large B-cell Lymphoma
- Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czech Republic, Czechia, Egypt, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Lebanon, Mexico, New Zealand, Norway, Peru, Poland, Russian Federation, Saudi Arabia, Singapore, Slovakia, South Africa, Spain, Switzerland, Thailand, Turkey, United Arab Emirates, United States, Venezuela
- 2008-11-11
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY
- Arabia Saudi, Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czech Republic, Egypt, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea North, Lebano, Mexico, New Zealand, Norway, Poland, Russian Federation, Singapore, Slovakia, South Africa, Spain, Switzerland, Thailand, Turkey, United Arab Emirates, United States, Venezuela
- 2011-11-24
Not Recruiting
- Bioavailability of the fixed dose formulation Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and the World Health Organization (WHO) recommended first line antiretroviral drugs zidovudine, lamivudine, efavirenz administered to new Tuberculosis (TB) patients at different levels of immunosuppression
- Tuberculosis (TB) and Human immunodeficiency virus (HIV) Infections and Infestations Human immunodeficiency virus (HIV)
- South Africa
- 2006-03-29
Not recruiting
- Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
- Breast Neoplasm;Breast Neoplasm;Breast Neoplasm;Breast Neoplasm
- Australia, Austria, Belgium, France, Germany, Ireland, Israel, Italy, New Zealand, Portugal, Spain, United Kingdom
- 2007-04-19
Not recruiting
- A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
- B-cell Chronic Lymphocytic Leukemia
- Australia, Austria, Belgium, Canada, Colombia, Czech Republic, Czechia, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, United Kingdom, United States
- 2008-10-16
Recruiting
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second Line Therapy (THE CONTINUUM TRIAL)
- B-cell Chronic Lymphocytic Leukemia;C91.1 - Chronic lymphocytic leukaemia
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, United Kingdom, United States
- 2012-10-12
Recruiting
- A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single autologous stem cell transplantation as part of front-line therapy
- Multiple Myeloma
- Australia, New Zealand
- 2016-06-14
Recruiting
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
- Breast Cancer
- Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Japan, Korea, Republic of, New Zealand, Poland, Portugal, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2018-10-29
Not recruiting
- Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent
- HIV-1
- Senegal
- 2013-01-16
Not recruiting
- Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
- HIV-1 Infection
- Congo
- 2013-01-14